• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Promising new agents in the treatment of non-small cell lung cancer.

作者信息

Edelman M J, Gandara D R

机构信息

Division of Hematology and Oncology, University of California, Davis, USA.

出版信息

Cancer Chemother Pharmacol. 1996;37(5):385-93. doi: 10.1007/s002800050402.

DOI:10.1007/s002800050402
PMID:8599859
Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

摘要

相似文献

1
Promising new agents in the treatment of non-small cell lung cancer.
Cancer Chemother Pharmacol. 1996;37(5):385-93. doi: 10.1007/s002800050402.
2
New chemotherapeutic agents for non-small cell lung cancer.
Chest. 1995 Jun;107(6 Suppl):306S-311S. doi: 10.1378/chest.107.6_supplement.306s.
3
New drug for therapy of non-small cell lung cancer.用于治疗非小细胞肺癌的新药。
Lung Cancer. 1994 Nov;11 Suppl 3:S139-49. doi: 10.1016/0169-5002(94)91874-0.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Rationale for non-platinum chemotherapy in advanced NSCLC.晚期非小细胞肺癌非铂类化疗的理论依据。
Oncology (Williston Park). 2001 Jul;15(7 Suppl 8):29-34.
6
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.紫杉醇、多西他赛、吉西他滨和长春瑞滨治疗非小细胞肺癌的临床疗效及成本效益：一项系统评价
Thorax. 2002 Jan;57(1):20-8. doi: 10.1136/thorax.57.1.20.
7
Radiosensitization with chemotherapeutic agents.化疗药物的放射增敏作用。
Lung Cancer. 2001 Dec;34 Suppl 4:S81-90. doi: 10.1016/s0169-5002(01)00382-8.
8
New drugs for treating small cell lung cancer.治疗小细胞肺癌的新药。
Lung Cancer. 1995 Jun;12 Suppl 3:S53-61. doi: 10.1016/s0169-5002(10)80018-2.
9
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].[非小细胞肺癌（NSCLC）IV期的新治疗方法]
Rev Pneumol Clin. 2001 Nov;57(5 Pt 2):S42-5.
10
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.新型化疗药物延长非小细胞肺癌患者生存期并改善生活质量：文献综述与未来方向
Clin Cancer Res. 1998 May;4(5):1087-100.

引用本文的文献

1
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.铂类/培美曲塞联合方案与其他铂类方案对可切除肺腺癌辅助化疗的影响。
Sci Rep. 2017 May 3;7(1):1453. doi: 10.1038/s41598-017-01347-6.
2
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.铂类双联疗法一线治疗中国晚期非鳞状非小细胞肺癌患者的临床疗效和临床毒性：一项回顾性队列研究
BMC Cancer. 2014 Dec 12;14:940. doi: 10.1186/1471-2407-14-940.
3

本文引用的文献

1
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.甲氨蝶呤乙酯加卡铂治疗晚期实体瘤的I期试验：冰片冷冻疗法改善剂量限制性粘膜炎。
Invest New Drugs. 1998;16(1):69-75. doi: 10.1023/a:1006026928733.
2
Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.通过中位效应分析评估依达曲沙和顺铂联合使用对A549肺癌细胞系的时间依赖性协同作用。
Cancer Chemother Pharmacol. 1993;33(3):245-50. doi: 10.1007/BF00686223.
3
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).
鉴定多西紫杉醇耐药的人非小细胞肺癌细胞（SPC-A1）中的 microRNA 图谱。
J Cell Mol Med. 2010 Jan;14(1-2):206-14. doi: 10.1111/j.1582-4934.2009.00964.x. Epub 2009 Nov 9.
4
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.人乳腺癌活检组织中化疗靶基因mRNA表达的定量分析：实时逆转录PCR与利用PCR产物DNA测序仪分析的相对定量逆转录PCR的比较
J Clin Lab Anal. 2003;17(5):184-94. doi: 10.1002/jcla.10091.
5
Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress.在经历低剂量紫杉醇诱导的有丝分裂应激的人类淋巴瘤细胞中凋亡的延迟表达。
Br J Cancer. 2003 May 19;88(10):1649-58. doi: 10.1038/sj.bjc.6600905.
6
Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience.
Invest New Drugs. 1998;16(3):265-70. doi: 10.1023/a:1006126505910.
7
Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.吉西他滨与长春地辛用于既往未治疗的不可切除非小细胞肺癌患者的II期研究。
Br J Cancer. 1999 Feb;79(5-6):875-81. doi: 10.1038/sj.bjc.6690140.
8
Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.紫杉醇对人肺癌异种移植瘤的抗肿瘤疗效。
Jpn J Cancer Res. 1997 Dec;88(12):1205-10. doi: 10.1111/j.1349-7006.1997.tb00350.x.
使用大剂量洛哌丁胺控制腹泻对伊立替康（CPT-11）进行高剂量递增。
J Natl Cancer Inst. 1994 Mar 16;86(6):446-9. doi: 10.1093/jnci/86.6.446.
4
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.长春瑞滨与顺铂联合、长春地辛与顺铂联合及单用长春瑞滨治疗晚期非小细胞肺癌的随机研究：一项纳入612例患者的欧洲多中心试验结果
J Clin Oncol. 1994 Feb;12(2):360-7. doi: 10.1200/JCO.1994.12.2.360.
5
Phase II study of topotecan in metastatic non-small-cell lung cancer.拓扑替康治疗转移性非小细胞肺癌的II期研究。
J Clin Oncol. 1994 Feb;12(2):347-52. doi: 10.1200/JCO.1994.12.2.347.
6
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.紫杉醇用于未经治疗的晚期非小细胞肺癌患者的II期研究。
J Natl Cancer Inst. 1993 Mar 3;85(5):384-8. doi: 10.1093/jnci/85.5.384.
7
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.每周吉西他滨单药治疗晚期非小细胞肺癌的疗效：一项II期研究。
J Clin Oncol. 1994 Sep;12(9):1821-6. doi: 10.1200/JCO.1994.12.9.1821.
8
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.吉西他滨治疗非小细胞肺癌的疗效与安全性：一项II期研究。
J Clin Oncol. 1994 Aug;12(8):1535-40. doi: 10.1200/JCO.1994.12.8.1535.
9
Gemcitabine: current status of phase I and II trials.吉西他滨：I期和II期试验的现状
J Clin Oncol. 1994 Aug;12(8):1527-31. doi: 10.1200/JCO.1994.12.8.1527.
10
Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line.在A549人非小细胞肺癌细胞系中，依达曲沙对卡铂内在体外耐药性的调节作用。
Oncol Res. 1994;6(3):151-6.